drugset / Trial / NCT02444455

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury

NCT02444455

NaSingle-groupOpen-labelTreatment

Summary

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.

Timeline

Start
2015-05
Primary completion
2017-03
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 500000 cells/kg Intravenous